10-K/A: Masimo Corporation Files Amendment to 2023 Annual Report, Includes Omitted Information

Masimo Corporation has filed an amendment to its 2023 annual report to include previously omitted information regarding directors, executive compensation, and other corporate governance matters.

Summary

• Masimo Corporation filed an amendment to its original 2023 Form 10-K to include information previously omitted from Part III, specifically items 10 through 14.
• This amendment includes details about the company's directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and accounting fees.
• The original Form 10-K was filed on February 28, 2024, and this amendment was filed because the company does not intend to file a definitive proxy statement containing the required information within the 120-day period after the fiscal year end.
• The amendment also includes new certifications from the principal executive officer and principal financial officer.
• No financial statements are included in this amendment, and it does not modify any other information from the original filing.

Sentiment

Score: 5

Explanation: The document is neutral in tone, providing factual information about the company's executive compensation and governance practices. While there are some negative aspects, such as the failure to meet bonus targets, the document primarily focuses on disclosure and compliance.

Positives

• The company has responded to stockholder feedback by making changes to its executive compensation program.
• The company has a robust stock ownership policy for executives and directors.
• The company has a clawback policy in place to recover erroneously awarded incentive-based compensation.
• The company has a policy prohibiting tax gross-up payments on post-employment compensation arrangements.
• The company has a policy prohibiting hedging of company stock by employees and directors.

Negatives

• The company did not pay any annual cash bonuses to its NEOs for fiscal year 2023 due to not meeting minimum performance thresholds.
• The company's 2021 PSU awards only paid out 28% of the target amount due to not meeting performance goals.
• The company's say-on-pay vote at the 2023 annual meeting only received 56% support from stockholders.

Risks

• The company's executive compensation program is complex and may be difficult for investors to understand.
• The company's performance-based compensation is tied to financial metrics that may not be achieved.
• The company's stock price may be volatile, which could impact the value of equity awards.
• The company faces competition from larger companies with greater resources.
• The company's business is subject to rapid product development and technological advances.

Future Outlook

The document does not contain specific forward-looking statements or guidance, but it does outline changes to the 2024 incentive compensation program.

Management Comments

• The Board believes it is important to be responsive to feedback from our stockholders about our executive compensation program.
• The Compensation Committee is committed to promoting a performance-based culture.
• The Board believes that Mr. Kiani is critical in his roles as Chairman and CEO to our continued development and growth.

Industry Context

The document provides insight into Masimo's executive compensation practices within the medical device industry, highlighting the need to attract and retain top talent in a competitive environment. The company's focus on performance-based compensation aligns with industry trends.

Comparison to Industry Standards

• The company uses a peer group of comparable companies to assess its executive compensation levels, including companies like ABIOMED, Insulet, and Align Technology.
• The peer group companies had median revenues of $2.4 billion, ranging from approximately $974 million to approximately $5.2 billion, based on the four fiscal quarters ended nearest to December 31, 2022.
• The peer group had a median market capitalization of $8.4 billion, ranging from approximately $2.3 billion to $34.4 billion, as of December 31, 2022.
• The company's compensation practices are designed to be competitive with these peer companies, while also aligning with the company's specific goals and objectives.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a cross-licensing agreement with Willow Laboratories, Inc., where Joe Kiani is also the Chairman and CEO, with royalty payments of approximately $19.2 million in fiscal 2023.
• The company has a services agreement with Willow Laboratories, Inc., with payments of approximately $0.5 million for general and administrative services in fiscal 2023.
• The company leases office space to Willow Laboratories, Inc., with lease income of approximately $1.2 million in fiscal 2023.
• The company made cash contributions of approximately $1.0 million to the Masimo Foundation for Ethics, Innovation and Competition in Healthcare in fiscal 2023.
• The company incurred $1.5 million in marketing expenses payable to Like Minded Media Ventures in fiscal 2023.

Stakeholder Impact

• The company's executive compensation program is designed to align the interests of executives with those of stockholders.
• The company's stock ownership policies encourage executives and directors to have a long-term stake in the company's success.
• The company's clawback policy protects stockholders from financial harm due to accounting restatements.
• The company's compensation committee has engaged with stockholders to understand their concerns about executive compensation.

Next Steps

• The company will continue to monitor and adjust its executive compensation program based on stockholder feedback and company performance.
• The company will disclose the performance goals for the Adjusted Revenue and Non-GAAP Operating Income metrics for the 2023 PSU awards following the conclusion of the performance period.
• The company will disclose details regarding the established threshold, target and maximum goals for each metric in the 2024 annual incentive in next year's proxy statement.

Key Dates

Keywords

executive compensation, corporate governance, directors, stock options, performance share units, financial metrics, annual report, proxy statement, incentive plans, stock ownership